Oncology

Prostate Cancer

Prostate-Specific Antigen (PSA) – standard screening test

A protein produced by ‘normal’, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man's blood. Elevated PSA levels may be indicative of a prostate issue requiring further investigation.

Stockholm3 - advanced screening test

A simple blood test to screen for risk of aggressive prostate cancer, which can be performed on men with PSA as low as 1.5 ng/mL who would not otherwise be detected. It analyses protein markers and genetic information alongside clinical data, giving a risk score and clear directions for further investigation (hisk risk) or to retest in the future (low risk).

SelectMDX - advanced screening test

Urine test collected in-clinic following DRE, which analyses mRNA biomarkers, PSA, prostate volume and age, in an algorithm to assess risk of aggressive prostate cancer. Gives a clear Yes/No answer to whether MRI/biopsy is required, which is more accurate than PSA alone. This reduces the number of unnecessary biopsies and increases the likelihood that aggressive prostate cancer will be detected early.

Proclarix - screening and/or alongside MRI

A simple protein-based blood test that can be done with the same sample as the PSA test. No additional intervention is required with results becoming quickly available. Patients with a PSA level between 2 and 10 ng/ml are in a diagnostic grey zone. Proclarix helps doctors and patients with PSA levels in the grey zone. Its Proclarix Risk Score delivers clear and immediate diagnostic support for further treatment decisions.

Prostatype – after diagnosis

Prostatype®'s unique system identifies the genetic fingerprint of cancer by measuring information from cancer stem cell genes. The gene expressions together with other clinical parameters such as PSA, Gleason and Tumour stage are entered into the Classification of Prostatic Malignancy Algorithm (CPMA) software that is linked to a unique patient data base. The software calculates a P-score which provides a measure of how aggressive the cancer is, facilitating the choice of optimal treatment for the patient.

HRR panel

Used to determine genetic predisposition or as a companion diagnostic tool down the line.

Bladder Cancer

PD-L1

Testing is available to clinicians in order to guide treatment options in immunotherapy.

Bladder Epicheck

Bladder EpiCheck provides patients and clinicians with a simple urine test to detect recurrence of bladder tumours. The test analyses subtle disease-specific changes in DNA methylation markers, allowing for the detection of 92%1 of the high-risk (non-Ta-LG) cancers.

Stomach Cancer

Her2

HER2 is a growth-promoting protein – in some people with stomach cancer the cancer cells have too much of this on their surface. Cancer cases with higher than normal levels of HER2 are called HER2-positive. These cancers are much more likely to respond to treatment with drugs that target the HER2 protein.

Breast Cancer

Her2

HER2 is a growth-promoting protein on the outside of all breast cells. Breast cancer cells with higher than normal levels of HER2 are called HER2-positive. These cancers tend to grow and spread faster than other breast cancers but are much more likely to respond to treatment with drugs that target the HER2 protein.

BRCA

We offer testing of both germline and somatic mutations to guide treatment pathways and give genetic information to families with a history of breast cancer

PD-L1

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. Recent discoveries in TNBC have shown that the higher the expression of the surface molecule PD-L1 in the cancer cells, the better the response of patients to immunotherapy. Testing is available to clinicians in order to guide treatment options in immunotherapy.

Pik3CA cf & Pik3CA Tissue

PIk3CA is a common genetic mutation in breast cancer patients and the gene has been associated with tumour growth, therapy resistance and poor prognosis. Patients who are HR+/HER2- may be able to take new targeted kinase inhibitors if they are one of the ~40% of patients with an activating PIK3CA mutation. CCL offers PIK3CA mutation analysis from tumour samples and liquid biopsies covering the Mutation hotspots in Exon 7, 9 and 20.

Lung Cancer

EarlyCDT Lung

A simple blood test to identify people with a heightened risk of lung cancer for triage into CT scanning.

EGFR

EGFR mutation testing works to detect mutations in the EGFR gene within the DNA of the tumour cells. This assists clinicians to determine whether someone with non-small cell lung cancer may benefit from targeted therapy with tyrosine kinase inhibitors.

PD-L1

Testing is available to clinicians in order to guide treatment options in immunotherapy.

ALK FISH & ROS-1 FISH

Looking at the ALK and ROS1 genes - helping to determine whether a person with non-small cell lung cancer will respond to a targeted drug therapy.

RET

Analysing the RET gene to help determine whether a person with non-small cell lung cancer will respond to a targeted drug therapy.

KRAS

Looking at the KRAS gene especially G12C mutation- helping to determine whether a person with non-small cell lung cancer will respond to a targeted drug therapy.

Bowel Cancer

FAECAL IMMUNOCHEMICAL TEST (FIT)

The standard test for the detection of occult blood in faeces and the only quantitative Faecal Immunochemical Test product with FDA approval.

RAS – RAF

BRAF, KRAS, and NRAS are the most frequent predictive biomarkers for bowel cancer treatment. Testing is available to clinicians in order to guide treatment options.

BRAF

Rapid real time PCR detection of mutations in BRAF codon 600 from tissue. Testing is available to clinicians in order to guide treatment options.

Thyroid Cancer

RET

Looking at fusions and mutations in the RET gene - helping to determine whether a person with advanced thyroid cancer will respond to a targeted drug therapy.